Supplementary Data from Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Supplementary information of the manuscript Table S1. Outcome to prior therapy in cohort A and cohort B Table S2. Response according to molecular profile in Cohort A Table S3. Response according to molecular profile in Cohort B Tables S4. Efficacy outcome according to type of MET deregulation Table S5. Adverse events (AEs) in Cohort A and Cohort B Table S6. List of serious adverse events (SAE) as reported by investigators Table S7. List of all participating Institutions